Urological Cancer 2020

doi:10.3390/books978-3-0365-0271-7

Download Url(s)

https://mdpi.com/books/pdfview/book/4203

Contributor(s)

López, José I. (editor)

Language

English

Show full item record

Abstract

This Urological Cancer 2020 collection contains a set of multidisciplinary contributions to the extraordinary heterogeneity of tumor mechanisms, diagnostic approaches, and therapies of the renal, urinary tract, and prostate cancers, with the intention of offering to interested readers a representative snapshot of the status of urological research.

URI

https://directory.doabooks.org/handle/20.500.12854/76754

Keywords

renal cell carcinoma; iron; macrophages; chelation therapy; urothelial carcinoma; transcriptome; microtubule; MAP1B; prognosis; KLF5; androgen receptor; cell proliferation; tumorigenesis; prostate cancer; precision medicine; whole genome sequencing; optical mapping; therapy; prostate carcinoma; prostate mpMRI; machine learning; artificial intelligence; deep learning; neural network; angiogenesis; angiogenic growth factors; antiangiogenic therapy; renal tumors; prevention; α1-adrenoceptor antagonists; anoikis; vascularity; research model; oncogenes; tumor suppressor genes; MR-guided; radiotherapy; MRgRT; stereotactic ablative radiotherapy; stereotactic ablative radiation therapy (SABR); renal cell cancer; RCC; online adaptive; [68Ga]Ga-PSMA PET/CT; dual-time point imaging; delayed imaging; biphasic imaging; lesion positivity rate; CXCL9; PD1; PD-L1; stage T1 NMIBC; prostatic neoplasms/mortality; prostatic neoplasms/epidemiology; SEER Program; bladder cancer; transurethral resection; en-bloc resection; CPT1A; fatty acids; serine; androgen response; ROS; oxidative stress; DONSON; Downstream Neighbor of SON; biomarker; metastatic spread; diagnosis; differential diagnosis; histopathology; immunohistochemistry; stroma signature; patient-derived xenografts; n/a